Artwork for podcast MAP - Market Access Podcast
What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?
Episode 63 • 16th April 2024 • MAP - Market Access Podcast • Dr. Stefan Walzer
00:00:00 00:31:28

Share Episode

Shownotes

Tune into a brand new episode of the Market Access Podcast to listen to an intriguing conversation about the Italian healthcare system with Giacomo Matteo Bruno and Dr Stefan Walzer. Together they explore the balance between innovation, sustainability, and patient access in the heart of Europe. Discover the evolution, challenges, and future of healthcare in Italy, from the foundational principles laid down in 1978 to the dynamic, ever-evolving landscape of today.

Giacomo shares his insights on how to navigate the crucial role of health economics in drug pathways as well as giving a birds-eye perspective over the healthcare system in Italy today and the challenges that comes with an aging population and rising chronic diseases. Giacomo presents a vision for embracing innovation while maintaining the system’s integrity. 

If you are searching for deeper knowledge about the Italian healthcare system and learn about strategies on how to enter the Italian market, this episode is for you. Learn about the regional nuances that make Italy unique, the steps for drug reimbursement, and the importance of targeted therapies in personalized medicine. Giacomo also sheds light on the pioneering electronic dossier system introduced by IFA, streamlining the approval process and setting a new standard in healthcare innovation.

Whether you're a healthcare professional, a pharmaceutical company, or just intrigued by the global healthcare landscape, this conversation offers valuable lessons and strategies for success in one of the world's most revered healthcare systems. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: MAP Podcasts

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#HealthcareInnovation #MarketAccess #Italy #ItalianHealthcare #PharmaceuticalIndustry #marketaccesspodcast #marketaccess

Chapters

More Episodes
63. What Makes Italy's Healthcare System So Complex, Giacomo Matteo Bruno?
00:31:28
62. Is Healthcare Just a Business in the US, Aymeric Chaupin?
00:33:06
61. A Flourishing Career in Pharmaceutical Market Access: Which Skills Are Essential, Dipti Tankala?
00:32:02
60. Mastering US Market Access: What are proven Strategies for Success, Paul-Lukas Hoffschmidt?
00:33:08
59. Beyond the CE Mark: How can we achieve Medtech Reimbursement in France, Dr. Benoit Salaun?
00:34:25
58. Remo Christen – Early paid access in Switzerland – Switzerland, wonderland? (Repost)
00:34:11
57. How can we overcome the complexity of market access for medical devices in Spain, Sergio Gil?
00:33:15
56. What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian? (Repost)
00:33:41
55. The Startup Guide to Navigating Healthcare Reimbursement, Featuring Ron de Graaff
00:33:53
54. Navigating the Healthcare Startup Galaxy - key insights with Dr. Thomas Kerscher and Mark Anken.
00:34:06
53. How to navigate complexities, Aurelie Moser: Market Access in Digital Health vs. Drugs?
00:32:00
52. AMNOG 2.0 - significant changes for the industry since January 2023, correct - Dr. Flume?
00:31:00
51. Inside the Swiss decision-makers - how does the system for drugs really work, Dr. Heiner Sandmeier?
00:36:26
50. How should market access and medical affairs work together, Dr. Mike Rosenblatt?
00:30:48
49. 📠 How will Switzerland make the leap from FAX machines to Digital Healthcare, Dr. Peter Indra?
00:29:04
48. How does an optimized communication strategy look like, Dr. Arne Näveke?
00:32:02
47. How does the German evaluation committee work, Prof. Jürgen Wasem?
00:34:26
46. How to optimize commercialisation of innovative life science products, Dr. Kasia Hein-Peters?
00:31:28
45. How do I get approved by the US FDA, Dr. Jamie Cross?
00:46:14
44. How will the US Inflation Reduction Act change pricing of pharmaceuticals, Anita Burrell?
00:35:02
43. How does market access work in Japan, Heather Wellam?
00:30:36
42. Would AI substitute or (only) support market access managers, Dr. Andree Bates? (Repost)
00:31:30
41. Is there a place for Real World Evidence in HTA, Dr. Karen Facey?
00:33:26
40. How can people get equal access to pharmaceuticals, Dr. Nina Lathia?
00:29:50
39. How to be successful in Canadian health care market access & pricing!
00:45:50
38. How can companies prepare for EU Joint HTA, Priyanka Kiritharan and Chloe Sheppard?
00:35:04
37. Is quality cancer care in Ukraine still possible, Yevgen Brovko?
00:21:20
36. What are drivers for a positive approval by Health Canada, Fraidianie Sévignè?
00:32:34
35. EU joint HTA – decided, but how will it be executed and how should companies prepare, Dr. Elvira Müller?
00:33:12
34. The US pricing reform has an impact on Europe as well, correct Dr. Renato Dellamano and Jack Mycka?!
00:36:42
33. What are the main obstacles in oncology market access, Ed Schoonveld?
00:38:28
32. Why should companies get early advice from payers, Esther Nzenza and Dr. Nick Leach?
00:38:38
31. The AMNOG process - how does it work from a legal perspective, Alexander Meier?
00:39:24
30. What are the hot topics in market access based on ISPOR Europe 2022, Dr. Stefan Walzer?
00:52:14
29. AMNOG Reform - will Germany remain the most attractive market for orphan drugs?
00:41:04
28. Why should Market Access Managers care about statistics, Alexander Schacht?
00:35:42
27. How might digitization change health care in Germany by 2035, Julian Molitor?
00:30:56
26. Are selective contracts with German insurances a smarter reimbursement pathway, Tim Hering?
00:28:06
25. Would AI substitute or (only) support market access managers, Dr. Andree Bates?
00:31:30
24. How successful is the DiGA fast track, Dr. Henrik Matthies ?
00:33:40
23. The UK market access has always been complex, now even more than before, Graham Foxon and Paul Craddy?
00:33:54
22. Switzerland is strong in many aspects, so also in its health care system, Dr. Peter Indra?
00:34:30
21. AMNOG was the end of paradise for pharmaceutical companies, correct Prof. Hammerschmidt?
00:37:54
20. What is the secret of the cost-efficient healthcare system in Israel, Mirel Stelian?
00:33:41
19. Dutch payers are pragmatic, especially when discussing medical devices, isn’t it, Ron de Graaff?
00:34:11
18. The Belgium reimbursement pathway for digital health applications is similarly easy as in Germany, correct Katrien de Groote?
00:20:14
17. Is European market access really so difficult? Tell us the truth being successful in Europe, Esther Nzenza!
00:27:20
16. What can Europeans learn from Canada for the upcoming EU joint HTA, Gabriel Tremblay?
00:43:50
15. Digital Health Care is already fully utilized in the US, isn’t it?
01:01:28
14. Does the Italian reimbursement pathway allow for innovative drugs being highly priced, Dr. Stefano Capri and Dr. Entela Xoxi?
00:28:30
13. What are the specific elements about the Austrian market access pathway, Dr. Anna Bucsics?
00:30:04
12. The private health insurances as the entrance into German market access – is this true, Dr. Bastian Biermann?
00:35:44
11. How can a company derive the optimal price for their medical product, Dr. Renato Dellamano?
00:32:14
10. How do innovations reach patients in German hospitals, Dr. Sebastian Casu?
00:32:44
9. How does hospital funding work in Germany, Willi Wöllner?
00:36:08
8. Prof. Dr. Jürgen Wasem - What happens, when negotiations fail?
00:38:30
7. Dr. Michael Zuercher - Commercial attractiveness of the Swiss health care market – success starts with market access.
00:32:49
6. Prof. Peter Zweifel & Door Vonk - Digital innovation - from theory into practice!
01:01:02
5. Bibiane Schulte-Bosse - How to fight well in AMNOG negotiations.
00:34:37
4. Prof. Dr. David Matusiewicz & Dr. Anne Sophie Geier - 1 year DIGAs. Is the "fast track process" for digital health applications successful?
00:28:10
3. Remo Christen – Early paid access in Switzerland – Switzerland, wonderland??
00:34:11
2. Prof. Dr. Wagschal - What can we expect from the upcoming elections in Germany?
00:35:43
1. Dr. Mathias Flume - AMNOG will change in 2022, but how?
00:34:16